bioAffinity publishes clinical framework for CyPath Lung nodule testing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil falls 3% to one-week low as supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
July 27, 2026 8:08 AM EDTComprehensive clinical review outlines specialty-specific approaches for integrating the tests lung microenvironment analysis into diagnostic pathway
Framework includes protocols for pulmonology, primary care and oncology practices for detection of lung cancer and surveillance of survivors
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a... More
